Cargando…

CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells

The identification of the essential role of cyclin-dependent kinases (CDKs) in the control of cell division has prompted the development of small-molecule CDK inhibitors as anticancer drugs. For many of these compounds, the precise mechanism of action in individual tumor types remains unclear as the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Štětková, Monika, Growková, Kateřina, Fojtík, Petr, Valčíková, Barbora, Palušová, Veronika, Verlande, Amandine, Jorda, Radek, Kryštof, Vladimír, Hejret, Václav, Alexiou, Panagiotis, Rotrekl, Vladimír, Uldrijan, Stjepan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494941/ https://www.ncbi.nlm.nih.gov/pubmed/32934219 http://dx.doi.org/10.1038/s41419-020-02971-3

Ejemplares similares

A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein
por: Valianatos, Georgios, et al.
Publicado: (2017)

A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize
por: Kosztyu, Pavlína, et al.
Publicado: (2019)

Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds
por: Palušová, Veronika, et al.
Publicado: (2020)

RNA-seq Characterization of Melanoma Phenotype Switch in 3D Collagen after p38 MAPK Inhibitor Treatment
por: Čermák, Vladimír, et al.
Publicado: (2021)

Ubiquitin-specific peptidase 48 regulates Mdm2 protein levels independent of its deubiquitinase activity
por: Cetkovská, Kateřina, et al.
Publicado: (2017)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

A Novel Interaction between TFII-I and Mdm2 with a Negative Effect on TFII-I Transcriptional Activity
por: Cetkovská, Kateřina, et al.
Publicado: (2015)

Both Hypoxia-Inducible Factor 1 and MAPK Signaling Pathway Attenuate PI3K/AKT via Suppression of Reactive Oxygen Species in Human Pluripotent Stem Cells
por: Fojtík, Petr, et al.
Publicado: (2021)

Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480
por: Gudernova, Iva, et al.
Publicado: (2017)

Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines
por: Dostálová, Hana, et al.
Publicado: (2023)

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
por: Kryštof, Vladimír, et al.
Publicado: (2012)

miRBind: A Deep Learning Method for miRNA Binding Classification
por: Klimentová, Eva, et al.
Publicado: (2022)

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
por: Laroche-Clary, Audrey, et al.
Publicado: (2017)

Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma
por: Furgason, John M., et al.
Publicado: (2015)

MicroRNA-129 Inhibits Glioma Cell Growth by Targeting CDK4, CDK6, and MDM2
por: Moradimotlagh, Atieh, et al.
Publicado: (2019)

CDK4 inhibition diminishes p53 activation by MDM2 antagonists
por: Sriraman, Anusha, et al.
Publicado: (2018)

MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas
por: Grünewald, Inga, et al.
Publicado: (2016)

Transcriptome analysis of thermomorphogenesis in ovules and during early seed development in Brassica napus
por: Jedličková, Veronika, et al.
Publicado: (2023)

The plasmamembrane calmodulin–dependent calcium pump: a major regulator of nitric oxide synthase I
por: Schuh, Kai, et al.
Publicado: (2001)

Mammalian DIS3L2 exoribonuclease targets the uridylated precursors of let-7 miRNAs
por: Ustianenko, Dmytro, et al.
Publicado: (2013)

Inhibition of Post-Transcriptional RNA Processing by CDK Inhibitors and Its Implication in Anti-Viral Therapy
por: Holcakova, Jitka, et al.
Publicado: (2014)

Synthesis and Structural Optimization of 2,7,9-Trisubstituted purin-8-ones as FLT3-ITD Inhibitors
por: Tomanová, Monika, et al.
Publicado: (2022)

Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
por: AbuHammad, Shatha, et al.
Publicado: (2019)

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
por: Martinez-Monleon, Angela, et al.
Publicado: (2022)

Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature
por: Koelsche, Christian, et al.
Publicado: (2021)

Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-b]pyridazine Derivatives Identified by Scaffold Hopping
por: Břehová, Petra, et al.
Publicado: (2023)

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
por: Kovatcheva, Marta, et al.
Publicado: (2015)

NEEMP: software for validation, accurate calculation and fast parameterization of EEM charges
por: Raček, Tomáš, et al.
Publicado: (2016)

The effect of the sphingosine‐1‐phosphate analogue FTY720 on atrioventricular nodal tissue
por: Egom, Emmanuel E., et al.
Publicado: (2015)

Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia
por: Bertrand, Jeanluc, et al.
Publicado: (2022)

The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing
por: Ryan, Sean, et al.
Publicado: (2018)

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
por: Portman, Neil, et al.
Publicado: (2020)

Heterogeneous EGFR, CDK4, MDM4, and PDGFRA Gene Expression Profiles in Primary GBM: No Association with Patient Survival
por: González-Tablas, María, et al.
Publicado: (2020)

Anatomy of Mdm2 and Mdm4 in evolution
por: Tan, Ban Xiong, et al.
Publicado: (2017)

Adamantane-Substituted Purines and Their β-Cyclodextrin Complexes: Synthesis and Biological Activity
por: Rouchal, Michal, et al.
Publicado: (2021)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma
por: Pilotti, S, et al.
Publicado: (2000)

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
por: Klein, Mary E., et al.
Publicado: (2018)

Juvenile trabecular ossifying fibroma: Immunohistochemical expression of MDM2, CDK4 and p53 compared to conventional ossifying fibroma
por: Nikitakis, Nikolaos G., et al.
Publicado: (2022)

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
por: Portman, Neil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3987bclcbmkv673ff3fdeft9ko